Raymond James raised the firm’s price target on Fusion Pharmaceuticals to $16 from $15 and keeps a Strong Buy rating on the shares after the company provided a series of clinical and manufacturing updates ahead of the JPMorgan Healthcare conference next week. Should a pharma company make a move on Fusion given the recent flurry of M&A in the radiopharmaceuticals and targeted oncology space, the firm expects a bid “would come at a significant premium,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FUSN:
- RayzeBio downgraded to Hold from Buy at Truist
- Gracell downgrade, Fusion upgrade: Wall Street’s top analyst calls
- Recent M&A activity bodes well for Fusion Pharmaceuticals, says Oppenheimer
- Fusion Pharmaceuticals upgraded at Raymond James amid radiopharma M&A
- Fusion Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James